Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28539657 | 0.82 | KDM4E (0.43) | KDM1AKDM4EMAOAMAOBNOTUM | |
| SCHEMBL28201512 | 0.72 | MAOA (0.54) | KDM4EMAOAMAOBNOTUMALDH1A1 | |
| SCHEMBL16063426 | 0.72 | CNR1 (0.54) | KDM4EGRM5ADORA2AADORA1ALDH1A1 | |
| SCHEMBL1079479 | 0.72 | PIK3R2 (0.51) | GRM5NOTUMMAPTGAAPIK3R2 | |
| Hydrochloric Acid SCHEMBL28856319 | 0.71 | MAOA (0.53) | KDM4EMAOAMAOBNOTUMALDH1A1 | |
| SCHEMBL1080644 | 0.71 | HTR2A (0.49) | KDM4EALDH1A1 | |
| SCHEMBL21066932 | 0.71 | KDM4E (0.44) | KDM4EMAOAMAOBNOTUMALDH1A1 | |
| SCHEMBL1077899 | 0.70 | GRM5 (0.59) | GRM5ALDH1A1MAPTGAA | |
| SCHEMBL30334651 | 0.69 | KDM4E (0.50) | KDM4EMAOAMAOBNOTUMALDH1A1 | |
| Formic Acid SCHEMBL30427064 | 0.68 | MAOA (0.50) | KDM4EMAOAMAOBNOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885KDM4E 15/4885MAOA 415/4885 |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885KDM4E 15/4885MAOA 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.